China SXT Pharmaceuticals, Inc.
SXTC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SXTC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SXTC
China SXT Pharmaceuticals, Inc. is a small-cap pharmaceutical company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) products, with a limited revenue base and a history of relying on external financing to fund operations.
Key risk: Capital dependency
Market Cap
$1.6M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Mar 31, 2026.
China SXT Pharmaceuticals, Inc. is a small-cap pharmaceutical company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) products, with a limited revenue base and a history of relying on external financing to fund operations.
- Cash and cash equivalents and restricted cash were $28.2M as of March 31, 2026, up from $18.1M a year earlier [sec · filed 2026-07-01].
- Revenue for the fiscal year ended March 31, 2026 was $1.14M, a 35% decline from $1.74M in the prior year [sec · filed 2026-07-01].
- The company has an experienced management team with over 10 years of pharmaceutical and TCM industry experience [sec · filed 2025-07-31].
- China SXT has limited working capital and expects to need substantial additional financing, which may cause dilution to shareholders [sec · filed 2026-07-01].
What works
- The company has an experienced management team with extensive backgrounds in TCM research, development, and commercialization [sec · filed 2025-07-31].
- Cash position improved to $28.2M as of March 31, 2026, providing a near-term liquidity buffer [sec · filed 2026-07-01].
What to weigh
- Revenue declined 35% year-over-year to $1.14M for the fiscal year ended March 31, 2026, indicating shrinking top-line performance [sec · filed 2026-07-01].
- The company has limited working capital and will need to engage in capital-raising transactions, which could cause substantial dilution to shareholders [sec · filed 2026-07-01].
- China SXT has a history of relying on organic revenues and financing transactions to fund operations, with no assurance of future capital availability [sec · filed 2025-07-31].
From the filings
Quoted directly from source documents.
Cash position as of March 31, 2026
“As of March 31, 2026, we had cash and cash equivalents and restricted cash of $28,176,233”
SEC filings · July 1, 2026
Need for additional financing
“We will need to engage in capital-raising transactions in the near future. Such financing transactions may well cause substantial dilution to our shareholders”
SEC filings · July 1, 2026
Risks & what to watch (4)›
Key risks
- Capital dependency — The company has limited working capital and will need substantial additional financing, with no assurance of availability [sec · filed 2026-07-01].
- Revenue decline — Revenue fell 35% year-over-year to $1.14M for fiscal 2026, indicating shrinking business scale [sec · filed 2026-07-01].
- Dilution risk — Future capital-raising may involve issuance of securities with rights senior to existing shares, causing dilution [sec · filed 2026-07-01].
- Operational history — The company's historical results are not indicative of current lines of business, and it faces risks typical of early-stage companies [sec · filed 2025-07-31].
What to watch
- Ability to secure additional financing or generate sufficient revenues to sustain operations [sec · filed 2026-07-01].
- Trend in revenue and gross profit in upcoming fiscal periods [sec · filed 2026-07-01].
- Progress in research, development, and commercialization of TCM product candidates [sec · filed 2025-07-31].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run China SXT Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available China SXT Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$131K
| Holder | Shares | Value |
|---|---|---|
| sabby management, llc | 78,170 | $131K |
| royal bank of canada | 13 | $0 |
Short Interest
as of May 22, 2026- % of float
- 0.3%
- Days to cover
- 0.0
- Shares short
- 3,264
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SXTC short interestFrequently asked questions
What is the AI investment thesis for China SXT Pharmaceuticals, Inc.?
China SXT Pharmaceuticals, Inc. is a small-cap pharmaceutical company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) products, with a limited revenue base and a history of relying on external financing to fund operations.
Who is the CEO of China SXT Pharmaceuticals, Inc.?
Mr. Feng Zhou is the chief executive officer of China SXT Pharmaceuticals, Inc. (SXTC).
Where is China SXT Pharmaceuticals, Inc. headquartered?
China SXT Pharmaceuticals, Inc. (SXTC) is headquartered in Taizhou, China.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.